These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26118713)

  • 1. Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.
    Yuan J; Kang JL; Liao H; Wang XX; Nie ML; Shuai R; Deng C
    Anticancer Agents Med Chem; 2015; 15(10):1308-16. PubMed ID: 26118713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.
    Guo Y; Yuan J; Yin S; Wang X; Shuai R; Kang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1082-1087. PubMed ID: 28604448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.
    Zhong J; Kang J; Wang X; Jiang W; Liao H; Yuan J
    Med Oncol; 2015 Apr; 32(4):118. PubMed ID: 25782870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of Constitutively Active Mutant MKK6(E) With TAT-OSBP Induces Apoptosis in Human Ovarian Carcinoma HO8910 Cells.
    Liao H; Kang JL; Jiang WY; Deng C; Yuan J; Shuai R
    Int J Gynecol Cancer; 2015 Nov; 25(9):1548-56. PubMed ID: 26495757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
    Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
    Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
    Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
    Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 12. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.
    Zhao H; Li R; Wang X; Lu X; Hu M; Zhang J; Zhao X; Song X; Liu Y
    J Ovarian Res; 2020 Sep; 13(1):113. PubMed ID: 32958014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
    Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
    Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
    Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
    Sui M; Chen F; Chen Z; Fan W
    Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
    Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
    Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.